Business Description
Diamyd Medical AB
ISIN : SE0005162880
Share Class Description:
OSTO:DMYD B: Class BTotal Employee Number:
41Compare
Compare
Traded in other countries / regions
DMYD B.SwedenDMN.GermanyDYMDF.USA IPO Date
2013-05-20Description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.64 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.68 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45 | |||||
3-Year EBITDA Growth Rate | -4.9 | |||||
3-Year EPS without NRI Growth Rate | -2.6 | |||||
3-Year FCF Growth Rate | 0.6 | |||||
3-Year Book Growth Rate | -9.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.82 | |||||
9-Day RSI | 36.9 | |||||
14-Day RSI | 37.86 | |||||
3-1 Month Momentum % | -6.98 | |||||
6-1 Month Momentum % | -93.16 | |||||
12-1 Month Momentum % | -89.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.5 | |||||
Quick Ratio | 15.5 | |||||
Cash Ratio | 15.23 | |||||
Days Sales Outstanding | 39.47 | |||||
Days Payable | 1137.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -692.09 | |||||
Operating Margin % | -66877.91 | |||||
Net Margin % | -65964.19 | |||||
EBITDA Margin % | -63946.51 | |||||
FCF Margin % | -45122.09 | |||||
OCF Margin % | -44383.49 | |||||
ROE % | -112.07 | |||||
ROA % | -82.68 | |||||
ROIC % | -420.04 | |||||
3-Year ROIIC % | 9701.42 | |||||
ROC (Joel Greenblatt) % | -552.78 | |||||
ROCE % | -89.88 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 4.48 | |||||
PS Ratio | 336.67 | |||||
PB Ratio | 0.6 | |||||
Price-to-Tangible-Book | 0.6 | |||||
EV-to-EBIT | -0.19 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-Revenue | 127.53 | |||||
EV-to-Forward-Revenue | 386.08 | |||||
EV-to-FCF | -0.28 | |||||
Price-to-GF-Value | 0.07 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 0.77 | |||||
| Price-to-Net-Cash | 0.79 | |||||
Earnings Yield (Greenblatt) % | -526.32 | |||||
FCF Yield % | -123.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Diamyd Medical AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.43 | ||
| EPS (TTM) (kr) | -1.8 | ||
| Beta | 2.1556 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 104.91 | ||
| 14-Day RSI | 37.86 | ||
| 14-Day ATR (kr) | 0.051291 | ||
| 20-Day SMA (kr) | 1.0499 | ||
| 12-1 Month Momentum % | -89.87 | ||
| 52-Week Range (kr) | 0.896 - 17.88 | ||
| Shares Outstanding (Mil) | 154.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Diamyd Medical AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Diamyd Medical AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2027-01-28 | In 171 days | ||
| General meeting for 2026 | 2026-12-04 15:00 | In 117 days | ||
| Annual report for 2026 | 2026-11-13 | In 95 days | ||
| Fourth quarter earnings results for 2026 | 2026-10-07 | In 58 days | ||
| Third quarter earnings results for 2026 | 2026-06-24 | 1.10 (+1.85%) | ||
| Second quarter earnings results for 2026 | 2026-03-25 | 15.38 (-6.22%) | ||
| First quarter earnings results for 2026 | 2026-01-28 | 14.42 (+0.14%) | ||
| General meeting for 2025 | 2025-12-04 15:00 | 9.90 (-1.59%) | ||
| Annual report for 2025 | 2025-11-13 | 10.28 (+2.90%) | ||
| Fourth quarter earnings results for 2025 | 2025-10-08 | 11.08 (-1.25%) |
Show
Entries
Diamyd Medical AB Frequently Asked Questions
What is Diamyd Medical AB(OSTO:DMYD B)'s stock price today?
The current price of OSTO:DMYD B is kr1.01. The 52 week high of OSTO:DMYD B is kr17.88 and 52 week low is kr0.90.
When is next earnings date of Diamyd Medical AB(OSTO:DMYD B)?
The next earnings date of Diamyd Medical AB(OSTO:DMYD B) is 2026-10-07.
Does Diamyd Medical AB(OSTO:DMYD B) pay dividends? If so, how much?
Diamyd Medical AB(OSTO:DMYD B) does not pay dividend.
Press Release
Articles on Diamyd Medical AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers